Delcath Systems (DCTH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for May 15, 2025, to be held virtually; no physical attendance permitted.
Record date for voting eligibility is March 20, 2025; multiple classes of stock, including Common and Preferred, are entitled to vote, subject to certain limitations.
Proposals include director elections, amendments to equity and employee stock purchase plans, auditor ratification, and a say-on-pay advisory vote.
Board recommends voting FOR all proposals; proxy voting available online, by phone, or mail.
Voting matters and shareholder proposals
Election of two Class I directors (Gerard Michel and Gilad Aharon) for terms expiring in 2028.
Amendment to 2020 Omnibus Equity Incentive Plan to add 2,200,000 shares for equity awards.
Amendment to 2021 Employee Stock Purchase Plan to add 300,000 shares.
Ratification of CBIZ CPAs as independent auditor for fiscal year ending December 31, 2025.
Advisory vote on executive compensation (say-on-pay).
Shareholder proposals for the 2026 meeting must be submitted 120 days before the anniversary of this proxy statement's release.
Board of directors and corporate governance
Board consists of six members, with a majority classified as independent under Nasdaq rules.
Board is divided into three classes with staggered terms; leadership roles are separated between CEO and Chairman.
Committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent members.
Board skill set emphasizes diversity in experience, industry knowledge, and strategic insight.
Code of Conduct and anti-hedging/pledging policies in place; clawback policy adopted per Dodd-Frank requirements.
Latest events from Delcath Systems
- Record $85.2M revenue, positive net income, and strong 2026 growth outlook.DCTH
Q4 202526 Feb 2026 - Q2 revenue hit $7.8M with 80% margin; net loss widened, but U.S. growth and NTAP boost outlook.DCTH
Q2 20242 Feb 2026 - Q3 revenue hit $11.2M, net income $1.9M, and $25M raised from warrants; all debt eliminated.DCTH
Q3 202415 Jan 2026 - Registration allows up to $150M in securities to fund oncology growth and operations.DCTH
Registration Filing16 Dec 2025 - Virtual Annual Meeting to vote on directors, equity plans, auditor, and executive pay.DCTH
Proxy Filing2 Dec 2025 - FY2024 revenue hit $37.2M, driven by HEPZATO KIT and positive Q4 adjusted EBITDA.DCTH
Q4 20241 Dec 2025 - Q1 2025 saw $19.8M revenue, $1.1M net income, and strong U.S. expansion.DCTH
Q1 202526 Nov 2025 - Q2 2025 revenue hit $24.2M with strong margins, profitability, and clinical expansion.DCTH
Q2 202523 Nov 2025 - Q3 2025 revenue doubled to $20.6M, with strong margins and cash, but lower net income.DCTH
Q3 202513 Nov 2025